Print page content Print
Increase text size Decrease text size
Text Size


(Ceftiofur Crystalline Free Acid)

Two Doses, One solution for your sick horse.


EXCEDE® (ceftiofur crystalline free acid) Sterile Suspension is indicated for the treatment of lower respiratory tract infections in horses caused by susceptible strains of Streptococcus equi subspecies zooepidemicus (S. zooepidemicus). S. zooepidemicus is the most common bacterial pathogen isolated from equine respiratory infections.1-3

EXCEDE is the first and only FDA-approved antibiotic for horses that offers a full course of therapy in just two doses. EXCEDE reduces the treatment requirements from 10 once or twice daily doses of a comparative antibiotic, such as oral trimethoprim-sulfonamide (TMS), to just two doses. This makes treating equine respiratory infections less stressful for the horse and more convenient for the veterinarian and horse owner.

Collapse All
  • First and Only Sustained-Release Antibiotic

    • EXCEDE is the first and only antibiotic FDA-approved for horses that offers a full 10-day course of therapy in just two treatments.

    Fewer Doses

    • By providing 10 days of therapy in just two treatments, veterinarians can optimize compliance and convenience.
    • Fewer administrations mean less potential for missed doses.
    • Comparative treatments require 10 once or twice daily doses. Maintaining multiple treatments at consistent intervals can cause added stress for the horse as well as for those administering the medication. For a full course of therapy, your horse must receive the full dose at regular intervals as prescribed by a veterinarian.

    Safe and Effective

    • The use of EXCEDE provides veterinarians peace of mind, knowing they have selected a product that has been demonstrated to be both safe and effective in horses.
    • EXCEDE is FDA-approved for use in horses and is available through veterinary prescription only.
  • Shake well before using. Administer two intramuscular injections to the horse, four days apart (96 hours), at a dose of 1.5 mL per 100 pounds of body weight (3.0 mg/lb. or 6.6 mg/kg). A maximum of 20 mL per injection site may be administered. In clinical studies, administration of less than 10 mL per injection site minimized injection site reactions. Therapeutic drug concentrations are maintained for six days after the second injection or a total of 10 days from the beginning of treatment against S. zooepidemicus. Vial contents should be used within 12 weeks after the first dose is removed.


    • EXCEDE Sterile Suspension is available in 100-mL and 250-mL vials.
  • 1 Clark C, Greenwood S, Boison JO, et al. Bacterial isolates from equine infections in western Canada (1998-2003). Can Vet J. 2008;49:153-160.
    2 Raidal SL. Equine pleuropneumonia. Br Vet J. 1995;151:233-262.
    3 Warner AE. Bacterial pneumonia in adult horses. In: Smith BP, ed. Large animal internal medicine, 3rd ed. St Louis: CV Mosby; 2002:491-496.


People with known hypersensitivity to penicillin or cephalosporins should avoid exposure to EXCEDE. EXCEDE is contraindicated in animals with known allergy to ceftiofur or to the β-lactam group (penicillins and cephalosporins) of antimicrobials. Do not use in horses intended for human consumption. The administration of antimicrobials in horses under conditions of stress may be associated with diarrhea, which may require appropriate veterinary therapy. See full Prescribing Information.




We are Mon–Fri, 8:30am–8:00pm ET

This site is intended for U.S. Animal Healthcare Professionals. The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2021 Zoetis Services LLC. All rights reserved.